ARCHIVES OF GYNECOLOGY AND OBSTETRICS, cilt.280, sa.2, ss.169-175, 2009 (SCI-Expanded)
The development of imatinib as a therapeutic agent targeting BCR-ABL has increased the treatment options for chronic myeloid leukemia (CML) by significantly impacting outcomes, and imatinib is recommended by treatment guidelines as the first-line therapy. However, treatment of maternal CML with imatinib during gestation is not recommended because of the potential risk to the fetus.